CUREVAC NV revenue breakdown overview

CUREVAC NV revenue for the last year amounted to 53.80 M EUR, the most of which — 52.66 M EUR — came from its highest performing source at the moment, Transformative Medicines Based on Messenger Ribonucleic Acid, the year earlier bringing 66.21 M EUR. The greatest contribution to the revenue figure was made by Belgium — last year it brought CUREVAC NV 46.16 M EUR, and the year before that — 61.14 M EUR.